Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sugar-Free diet may shield hispanic kids from fatty liver

NCT ID NCT05292352

Prevention Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a low-sugar diet could prevent non-alcoholic fatty liver disease (NAFLD) in Hispanic children ages 6 to 9 who were at higher risk. Over two years, researchers compared kids who followed the diet with those who ate normally. The goal was to see if cutting sugar could stop fat from building up in the liver. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

103 people

The number who actually took part.

Started

Apr 2022

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 9 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. At least one parent or the child self-identifies as Hispanic or Latino. 2. BMI ≥ 50th percentile for age and sex. 3. Age ≥ 6 years and ≤ 9 years 4. Tanner stage 1 by self and/or parental report 5. Normal ALT on screening labs (≤23 IU for girls, ≤26 IU for boys) 6. Written informed consent from parent or legal guardian, assent from child Exclusion Criteria: 1. Known diagnosis of chronic liver disease other than NAFLD and "fatty liver" 2. History of significant depression 3. Implanted metal or other implant (braces ok), or claustrophobia or other reason that contraindicates MRI 4. Type 2 diabetes (Hemoglobin A1c \> 6.4% on screening labs or chronic diagnosis) 5. Plans to move within the next 12 months 6. Current or previous participation in a weight loss program or obesity treatment program or clinic 7. Cancer or history of cancer 8. Recipient of a liver transplant 9. Chronic use (in the last year) of medications known to cause NAFLD or fatty liver (TPN, amiodarone, chronic oral steroids, etc.) 10. Intellectual disability or major psychiatric disorder limiting informed assent 11. At risk for eating disorder by screening instrument 12. Participants who are currently enrolled in a clinical trial or have received an investigational product within the last 60 days 13. Participants who are not able or willing to comply with the diet protocol or have any other condition or circumstance that would impede compliance or hinder completion of the study in the opinion of the investigator 14. Children who spend more than 1 night per week consistently in another household

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-alcoholic fatty liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-alcoholic fatty liver disease

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30329, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.